All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What are the main advances in patient care that we are seeing with novel agents for leukemia?
Bookmark this article
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Guru Subramanian Guru Murthy, Medical College of Wisconsin, Milwaukee, US. We asked, What are the main advances in patient care that we are seeing with novel agents for leukemia?
What are the main advances in patient care that we are seeing with novel agents for leukemia?
Guru Murthy evaluates data on new targeted agents for ALL, including blinatumomab, an anti-CD19 bispecific antibody, and inotuzumab, an anti-CD22 antibody-drug conjugate. He also focuses on a new treatment for Philadelphia chromosome-positive ALL, using trial data investigating a chemotherapy-free approach that combined blinatumomab and ponatinib, a tyrosine kinase inhibitor (TKI).
Your opinion matters
6 votes - 49 days left ...
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox